Adipotide (10 mg Vial) Dosage Protocol
Adipotide is a synthetic peptidomimetic that targets prohibitin on blood vessels within white adipose tissue, delivering a pro-apoptotic sequence that destroys those vessels. Preclinical studies showed ~30% body weight reduction in obese rodents and ~11% in obese primates. Human clinical development was discontinued due to reversible kidney toxicity at higher doses.
⚡ Quickstart Highlights
Dosing & Reconstitution Guide
Educational guide for reconstitution and daily dosing
Standard / Gradual Approach (3 mL = ~3.33 mg/mL)
| Week | Daily Dose (mcg) | Units (per injection) (mL) |
|---|---|---|
| Weeks 1–2 | 250 mcg | 7.5 units (0.08 mL) |
| Weeks 3–4 | 500 mcg | 15 units (0.15 mL) |
| Weeks 5–6 | 750 mcg | 22.5 units (0.23 mL) |
| Weeks 7–8 | 1000 mcg (1.0 mg) | 30 units (0.30 mL) |
Frequency: Inject once daily subcutaneously. This schedule uses the largest practical dilution (3.0 mL) and starts at a conservative dose with gradual escalation to mitigate potential renal side effects observed at higher doses in preclinical studies. For ≤10‑unit (≤0.10 mL) administrations, consider 30‑ or 50‑unit insulin syringes for improved readability.
Reconstitution Steps
- Draw 3.0 mL bacteriostatic water with a sterile syringe.
- Inject slowly down the vial wall; avoid foaming.
- Gently swirl/roll until dissolved (do not shake).
- Label and refrigerate at 2–8 °C (35.6–46.4 °F), protected from light.
Important: This guide is for educational purposes only and is not medical advice. For research use only. Not for human consumption. Clinical development was discontinued due to safety concerns.
Supplies Needed
Plan based on an 8–week cautious titration protocol with once‑daily administration.
| Item | Quantity |
|---|---|
| Peptide Vials (Adipotide, 10 mg each) | 8 weeks: approximately 4 vials required 12 weeks: approximately 7 vials required 16 weeks: approximately 10 vials required |
| Insulin Syringes (U‑100) | Per week: 7 syringes (1/day) 8 weeks: 56 syringes 12 weeks: 84 syringes 16 weeks: 112 syringes |
| Bacteriostatic Water (10 mL bottles) | 8 weeks (4 vials): 12 mL — 2 bottles required (10 mL each) 12 weeks (7 vials): 21 mL — 3 bottles required (10 mL each) 16 weeks (10 vials): 30 mL — 3 bottles required (10 mL each) |
| Alcohol Swabs | Per week: 14 swabs (2/day) 8 weeks: 112 swabs — 2 boxes required (100 swabs each) 12 weeks: 168 swabs — 2 boxes required (100 swabs each) 16 weeks: 224 swabs — 3 boxes required (100 swabs each) |
Protocol Overview
Adipotide is a peptidomimetic that targets prohibitin on adipose tissue vasculature, destroying blood vessels feeding white fat. This protocol represents an extremely cautious educational reference — not a validated human treatment.
Storage Instructions
| State | Temperature | Duration |
|---|---|---|
| Lyophilized | −20°C (−4°F) | Up to 24 months, dry & dark |
| Reconstituted | 2–8°C (35–46°F) | Up to 30 days, protect from light |
Important Notes
How This Works
Adipotide binds prohibitin-1 on the vascular endothelium of white adipose tissue and delivers a pro-apoptotic sequence that triggers vessel destruction. Fat cells lose their blood supply, undergo apoptosis, and are metabolized. Preclinical models show highly targeted effects sparing other tissues.
Potential Benefits & Side Effects
Potential Benefits
- Preclinical: ~30% weight loss in rodents, ~11% in primates over 4 weeks.
- Mechanism specifically targets adipose vasculature.
Side Effect Profile
- ⚠ Reversible kidney toxicity observed at higher preclinical doses.
- Clinical development discontinued after Phase 1 due to safety.
- Mild injection-site reactions.
- Long-term human safety unknown.
Lifestyle Factors
- Balanced protein-forward diet.
- Monitor kidney function if cycling beyond 4 weeks.
- Sleep and stress management.
Injection Technique
- Subcutaneous, rotate sites daily.
- Slow injection.